RxDoctor Payments Data

Stephen Leslie

Urology · Omaha, NENPI 1598756959

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (41.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Alnylam Pharmaceuticals Inc. accounts for 80.2% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $5,953 and has fallen 99.0% since, to $57 in 2024.

$11,570in general payments, 2019–2025

Across 88 payments — averaging $131.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$9K
  • Astellas Pharma US Inc$572
  • AbbVie$274
  • Merck$134
  • Dornier Medtech America, Inc$116
  • Boston Scientific$115
  • plus $1K from 24 others

What the payments were for

  • Consulting fees$4,84042%
  • Travel & lodging$4,29237%
  • Food & beverage$1,98017%
  • Education$4584%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,570 in reported general payments places this provider in the 80th percentile of 79 urology providers in Nebraska.

See all urology providers in Nebraska

Other urology in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →